Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERI – Research Report) today. The company’s shares opened today at $15.21. Belanger covers the Healthcare sector, focusing on
Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERI – Research Report) today. The company’s shares opened today at $15.21. Belanger covers the Healthcare sector, focusing on
Bearish sentiment continues to have a strong impact on the U.S. stock market, and the healthcare sector has suffered as well, with a year-to-date decline of more than 15%. Some
Swiss eye-care company Alcon (NYSE:ALC) has signed a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for roughly $770 million. The deal, which is expected to boost Alcon’s financials,
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intra-Cellular Therapies (ITCI – Research Report), InflaRx (IFRX – Research Report) and Aerie Pharma (AERI – Research Report) with bullish sentiments.
Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies received a Buy rating and a $75.00 price target from Mizuho Securities analyst Graig Suvannavejh today. The company’s shares closed last Friday at $59.99, close to its 52-week high of $66.00.
According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of
Intra-Cellular Therapies has an analyst consensus of Strong Buy, with a price target consensus of $71.38.
See Insiders’ Hot Stocks on TipRanks >>
InflaRx (IFRX)
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx today and set a price target of $8.00. The company’s shares closed last Friday at $2.91.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of
InflaRx has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, representing a 70.1% upside. In a report issued on July 26, Raymond James also maintained a Buy rating on the stock.
Aerie Pharma (AERI)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Aerie Pharma today and set a price target of $20.00. The company’s shares closed last Friday at $8.91.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $15.33 average price target, which is an 118.1% upside from current levels. In a report issued on August 1, Truist Financial also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ITCI:
In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $14.00. The company’s shares closed last Thursday at $7.37.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 3.9% and a 45.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $15.33, a 125.4% upside from current levels. In a report issued on August 1, Truist Financial also maintained a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $17.21 and a one-year low of $4.81. Currently, Aerie Pharma has an average volume of 620.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Read More on AERI: